MindMed is a US clinical-stage biopharmaceutical company leveraging novel psychedelic medicines to target mental health conditions. The company has programs for the treatment of conditions such as generalized anxiety disorder, attention deficit hyperactivity disorder, autism spectrum disorder and opioid use disorder.
Healthcare |
edison tv
Healthcare |
edison tv
Healthcare |
edison tv
Maxim Jacobs
Vice President of Investor Relations and Corp
Robert Barrow
CEO
Schond Greenway
CFO
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 31.2 | (16.5) | 20.0 |
Relative | 18.7 | (17.5) | 4.4 |
52 week high/low | US$4.9/US$2.1 |